ReviewPharmacogenomics and personalized medicine2014
Finally sofosbuvir: an oral anti-HCV drug with wide performance capability.
Review in Pharmacogenomics and personalized medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 46 citations in OpenAlex.
- Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study.Scientific reports · 2019Trial
- Development of a Divergent Synthesis Strategy for 5-Sulfonyl-Substituted Uracil Derivatives.The Journal of organic chemistry · 2024Article
- Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective.Journal of medicinal chemistry · 2023Review
- Transcriptome-based analysis of human peripheral blood reveals regulators of immune response in different viral infections.Frontiers in immunology · 2023Article
- Nucleotide and nucleoside-based drugs: past, present, and future.Saudi journal of biological sciences · 2022Review
- Revolution in the diagnosis and management of hepatitis C virus infection in current era.World journal of hepatology · 2022Article
- Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.eLife · 2021Article
- Inhibition of SARS-CoV-2 polymerase by nucleotide analogs: a single molecule perspective.bioRxiv : the preprint server for biology · 2021Article
- Nucleotide analogues as inhibitors of SARS-CoV Polymerase.Pharmacology research & perspectives · 2020Article
- Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.Scientific reports · 2020Article
- Retreatment of Hepatitis C Infection With Direct-Acting Antivirals.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2020Article
- Identification of a Broad-Spectrum Viral Inhibitor Targeting a Novel Allosteric Site in the RNA-Dependent RNA Polymerases of Dengue Virus and Norovirus.Frontiers in microbiology · 2020Article
- Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships.Drug design, development and therapy · 2020Article
- Sofosbuvir induced leucocytoclasic vasculitis: a case report.BMC dermatology · 2019Article
- Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.Hepatology international · 2016Observational
- An insight into the molecular characteristics of hepatitis C virus for clinicians.Saudi medical journal · 2016Review
- Management of hepatitis C genotype 4 in the directly acting antivirals era.BMJ open gastroenterology · 2016Article
- Identification and Characterization of Liver MicroRNAs of the Chinese Tree Shrew via Deep Sequencing.Hepatitis monthly · 2015Article
- Synthesis and antiviral activity of a series of novel N-phenylbenzamide and N-phenylacetophenone compounds as anti-HCV and anti-EV71 agents.Acta pharmaceutica Sinica. B · 2015Article
- LRRFIP1 Inhibits Hepatitis C Virus Replication by Inducing Type I Interferon in Hepatocytes.Hepatitis monthly · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Chronic Hepatitis C virus (HCV) infection is the leading cause of advanced liver disease worldwide. The virus successfully evades host immune detection and for many years has hampered efforts to find a safe, uncomplicated, and reliable oral antiviral therapy. Initially, interferon and ribavirin therapy was the treatment standard of care, but it offered limited performance across the wide spectrum of HCV disease and was fraught with excessive and often limiting side effects. Sofosbuvir (SOF) is a potent first-in-class nucleoside inhibitor that has recently been approved for treatment of HCV. The drug has low toxicity, a high resistance barrier, and minimal drug interactions with other HCV direct-acting antiviral agents such as protease inhibitors or anti-NS5A agents. SOF is safe and can be used across different viral genotypes, disease stages, and special patient groups, such as those coinfected with human immunodeficiency virus. When used in combination with ribavirin or another direct-acting antiviral agent, SOF has revolutionized the HCV treatment spectrum and set the stage for nearly universal HCV antiviral therapy. More so than any other anti-HCV drug developed to date, SOF offers the widest applicability for all infected patients, and new regimens will be tailored to maximize performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.